News

Feb. 15. 2021

Sawai Receives Approvals for Eight Generic Drugs with 20 Strengths

Feb. 12. 2021

Sawai Reports Third Quarter FY2020 Financial Results

Jan. 28. 2021

Sawai and Neurolief enter into Exclusive Development and Marketing Agreement for Relivion

Dec. 16. 2020

Upsher-Smith Launches Ramelteon Tablets

Dec. 10. 2020

Sawai Launches Two Generic Drugs with 10 Strengths

Nov. 24. 2020

Notice of Convocation of an Extraordinary General Meeting of Shareholders and the Matters to be Resolved Thereat, as well as Partial Amendments to the Articles of Incorporation

Nov. 09. 2020

Sawai Reports First Half of FY2020 Financial Results

Oct. 19. 2020

Sawai Launches Dutasteride Capsules

Oct. 06. 2020

Sawai Receives Approval for Dutasteride Capsules

Aug. 17. 2020

Sawai Receives Approvals for 4 Generic Drugs with 13 Strengths

Aug. 11. 2020

Upsher-Smith and AmbioPharm Announce Partnership Agreement to Develop and Market Corticotropin Injection

Aug. 06. 2020

Sawai Reports First Quarter FY2020 Financial Results

Jul. 28. 2020

Notice of Transition to a Holding Company Structure through Sole-Share Transfer and Establishment of the Record Date for Convocation of an Extraordinary General Meeting of Shareholders

Jul. 02. 2020

Upsher-Smith Launches Propafenone Hydrochloride Extended-Release Capsules

Jun. 25. 2020

Upsher-Smith Launches Ethacrynic Acid Tablets, USP

Jun. 23. 2020

Sawai Launches Vardenafil Tablets

Jun. 22. 2020

Sawai and Neugen Pharma enter into Co-development and Definitive License Agreement for ALS Drug

Jun. 18. 2020

Sawai Launches 14 Generic Drugs with 29 Strengths

Jun. 04. 2020

Sawai Receives Approval for Vardenafil Tablets

May. 14. 2020

Sawai Reports FY2019 Financial Results

May. 14. 2020

Notice of Commencement of Preparation for Transition to a Holding Company Structure through Sole-Share Transfer

Mar. 23. 2020

Notice of Change in Representative Directors

Mar. 06. 2020

Sawai Launches Tadalafil Tablets

Feb. 20. 2020

Sawai Receives Approval for Tadalafil Tablets